FBN2 and plasma cell neoplasm: Data in Table 3 address the question “would the absence of the insertion prevent Activin subfamily binding?” The common plasma cell tumor phenotype for a cysteine mutation in INHBE and 3 mutations in TGF-β-binding domain-6 of FBN2 and FBN3 suggest it does not.